Role of Shiga toxin 2 (Stx2)-binding protein, human serum amyloid P component (HuSAP), in Shiga toxin-producing Escherichia coli infections:: assumption from in vitro and in vivo study using HuSAP and anti-Stx2 humanized monoclonal antibody TMA-15

被引:13
作者
Kimura, T
Tani, S
Motoki, M
Matsumoto, Y
机构
[1] Teijin Ltd, Teijin Inst Biomed Res, Hino, Tokyo 1918512, Japan
[2] Teijin Ltd, Pharmaceut Dev Dept 1, Chiyoda Ku, Tokyo 1008585, Japan
关键词
human serum amyloid P component; Shiga toxin 2; Shiga toxin-producing Escherichia coli infections; humanized monoclonal antibody; neutralization; passive immune therapy;
D O I
10.1016/S0006-291X(03)00901-X
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Shiga toxin 2 (Stx2) is a major pathogenic factor in Shiga toxin-producing Escherichia coli (STEC) infections. Some factor that neutralizes Stx2 in vitro had been shown to be specifically present in human serum and we recently identified it as human serum amyloid P component (HuSAP). Here, we report the role of HuSAP in STEC infections. HuSAP could not rescue Stx2-challenged mice from death, and it instead reduced the efficacy of the Stx2-neutralizing humanized monoclonal antibody TMA-15 when a lower dose of TMA-15 was injected to the mice. By contrast, the efficacy of TMA-15 at a higher dose was uninfluenced by the presence of HuSAP. These findings suggest that HuSAP acts as a carrier protein of Stx2 rather than as a Stx2-neutralizing factor in the human circulation and that passive immune therapy with Stx2-neutralizing antibodies such as TMA-15 is useful to prevent severe complications associated with STEC infections even in the presence of HuSAP. (C) 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:1057 / 1060
页数:4
相关论文
共 22 条
[1]   ANTICYTOTOXIN-NEUTRALIZING ANTIBODIES IN IMMUNE GLOBULIN PREPARATIONS - POTENTIAL USE IN HEMOLYTIC-UREMIC SYNDROME [J].
ASHKENAZI, S ;
CLEARY, TG ;
LOPEZ, E ;
PICKERING, LK .
JOURNAL OF PEDIATRICS, 1988, 113 (06) :1008-1014
[2]   Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity [J].
Bickerstaff, MCM ;
Botto, M ;
Hutchinson, WL ;
Herbert, J ;
Tennent, GA ;
Bybee, A ;
Mitchell, DA ;
Cook, HT ;
Butler, PJG ;
Walport, MJ ;
Pepys, MB .
NATURE MEDICINE, 1999, 5 (06) :694-697
[3]   DIFFERENCES IN VEROTOXIN NEUTRALIZING ACTIVITY OF THERAPEUTIC IMMUNOGLOBULINS AND SERA FROM HEALTHY CONTROLS [J].
BITZAN, M ;
KLEMT, M ;
STEFFENS, R ;
MULLERWIEFEL, DE .
INFECTION, 1993, 21 (03) :140-145
[4]   Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans [J].
Boerlin, P ;
McEwen, SA ;
Boerlin-Petzold, F ;
Wilson, JB ;
Johnson, RP ;
Gyles, CL .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (03) :497-503
[5]   PENTRAXIN-CHROMATIN INTERACTIONS - SERUM AMYLOID-P COMPONENT SPECIFICALLY DISPLACES H1-TYPE HISTONES AND SOLUBILIZES NATIVE LONG CHROMATIN [J].
BUTLER, PJG ;
TENNENT, GA ;
PEPYS, MB .
JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 172 (01) :13-18
[6]   HEMOLYTIC-UREMIC SYNDROME AND VERO CYTOTOXIN-PRODUCING ESCHERICHIA-COLI INFECTION IN ITALY [J].
CAPRIOLI, A ;
LUZZI, I ;
ROSMINI, F ;
PASQUINI, P ;
CIRRINCIONE, R ;
GIANVITI, A ;
MATTEUCCI, MC ;
RIZZONI, G .
JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (01) :154-158
[7]  
CAPRIOLI A, 1994, INT CONGR SER, V1072, P353
[8]   FIBRONECTIN AND C4-BINDING PROTEIN ARE SELECTIVELY BOUND BY AGGREGATED AMYLOID-P COMPONENT [J].
DEBEER, FC ;
BALTZ, ML ;
HOLFORD, S ;
FEINSTEIN, A ;
PEPYS, MB .
JOURNAL OF EXPERIMENTAL MEDICINE, 1981, 154 (04) :1134-1149
[9]   SITE OF ACTION OF A VERO TOXIN (VT2) FROM ESCHERICHIA-COLI O157-H7 AND OF SHIGA TOXIN ON EUKARYOTIC RIBOSOMES - RNA N-GLYCOSIDASE ACTIVITY OF THE TOXINS [J].
ENDO, Y ;
TSURUGI, K ;
YUTSUDO, T ;
TAKEDA, Y ;
OGASAWARA, T ;
IGARASHI, K .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1988, 171 (1-2) :45-50
[10]   THE EPIDEMIOLOGY OF INFECTIONS CAUSED BY ESCHERICHIA-COLI O157-H7, OTHER ENTEROHEMORRHAGIC ESCHERICHIA-COLI, AND THE ASSOCIATED HEMOLYTIC UREMIC SYNDROME [J].
GRIFFIN, PM ;
TAUXE, RV .
EPIDEMIOLOGIC REVIEWS, 1991, 13 :60-98